Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug

Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it...

Descripción completa

Detalles Bibliográficos
Autores principales: Padrón, J., Rojas, A., Glaría, L., Caveda, L., Delgado, R., Torres, M., Martínez, O., López, E., Beltrán, A., Palacios, M.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365655/
https://www.ncbi.nlm.nih.gov/pubmed/18475666
http://dx.doi.org/10.1155/S0962935195000597
Descripción
Sumario:Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it was found that CCA inhibits the production of guanosine 3',5'-cyclic monophosphate almost completely when present in concentrations of 1 mM. Further results demonstrated that such inhibition could also be explained by interference in constitutive nitric oxide generation. In addition to previous findings, more insight into the molecular mechanism of action of CCA is provided.

Ejemplares similares